Compare Stocks → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATRANASDAQ:CMPXNASDAQ:CRBUNASDAQ:SRNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$0.70+6.1%$0.72$0.20▼$3.02$78.90M0.691.12 million shs856,377 shsCMPXCompass Therapeutics$1.49+1.4%$1.84$1.15▼$3.62$202.26M0.78344,597 shs106,511 shsCRBUCaribou Biosciences$3.99+3.6%$5.76$3.44▼$8.59$347.71M2.481.58 million shs1.38 million shsSRNESorrento Therapeutics$0.02-40.0%$0.02$0.00▼$0.42$11.03M2.25273,022 shs136,932 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+5.51%+2.77%0.00%+16.04%-77.06%CMPXCompass Therapeutics+1.36%-5.70%-30.05%+3.47%-48.80%CRBUCaribou Biosciences+3.64%-1.97%-23.71%-24.72%-10.74%SRNESorrento Therapeutics-25.00%-50.00%+87.50%-40.00%-95.54%$25,000 into $109,616 in two months? (Ad)Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics3.8643 of 5 stars3.02.00.04.72.62.50.6CMPXCompass Therapeutics3.0435 of 5 stars3.55.00.00.02.33.30.0CRBUCaribou Biosciences1.3346 of 5 stars3.41.00.00.02.01.70.6SRNESorrento TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics2.00Hold$28.003,914.91% UpsideCMPXCompass Therapeutics3.00Buy$9.00504.03% UpsideCRBUCaribou Biosciences2.75Moderate Buy$22.50463.91% UpsideSRNESorrento TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest ATRA, CMPX, CRBU, and SRNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/22/2024CMPXCompass TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.003/21/2024CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/19/2024CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $24.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$8.57M9.71N/AN/A($0.97) per share-0.72CMPXCompass TherapeuticsN/AN/AN/AN/A$1.17 per shareN/ACRBUCaribou Biosciences$34.48M10.45N/AN/A$4.17 per share0.96SRNESorrento Therapeutics$62.84M0.13N/AN/A($0.05) per share-0.30Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)CMPXCompass Therapeutics-$42.49M-$0.34N/AN/AN/AN/A-26.07%-24.49%5/2/2024 (Estimated)CRBUCaribou Biosciences-$102.07M-$1.45N/AN/AN/A-296.05%-31.06%-25.73%5/14/2024 (Estimated)SRNESorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/A5/13/2024 (Estimated)Latest ATRA, CMPX, CRBU, and SRNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million3/21/2024Q4 2023CMPXCompass Therapeutics-$0.09-$0.11-$0.02-$0.11N/AN/A3/11/2024Q4 2023CRBUCaribou Biosciences-$0.22-$0.39-$0.17-$0.39$5.17 million$3.56 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.720.65CMPXCompass TherapeuticsN/A19.7319.73CRBUCaribou BiosciencesN/A11.9711.97SRNESorrento TherapeuticsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%CMPXCompass Therapeutics68.43%CRBUCaribou Biosciences77.51%SRNESorrento Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.50%CMPXCompass Therapeutics30.00%CRBUCaribou Biosciences9.50%SRNESorrento Therapeutics2.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableCMPXCompass Therapeutics32137.59 million96.31 millionNot OptionableCRBUCaribou Biosciences15890.32 million81.74 millionOptionableSRNESorrento Therapeutics799551.28 million536.95 millionOptionableATRA, CMPX, CRBU, and SRNE HeadlinesSourceHeadlineSorrento Therapeutics (NASDAQ:SRNE) Now Covered by StockNews.comamericanbankingnews.com - April 21 at 2:14 AMSorrento Therapeutics (NASDAQ:SRNE) Earns Hold Rating from Analysts at StockNews.comamericanbankingnews.com - April 13 at 2:18 AMSorrento Therapeutics Wins Appeal Over Covid Treatment Remarksnews.bloomberglaw.com - March 27 at 4:18 AMSorrento Therapeutics Wins Appeal Over Covid Treatment Remarksnews.bloomberglaw.com - March 27 at 4:18 AMSorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)news.bloomberglaw.com - March 12 at 6:20 PMJudge Declines to Dismiss Sorrento Therapeutics Bankruptcy Casewsj.com - March 12 at 6:20 PMVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.tmcnet.com - February 27 at 9:57 AMVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.businesswire.com - February 27 at 7:30 AMSorrento Therapeuticspharmaphorum.com - February 7 at 10:34 AM5 Sanders Cove, Sorrento WA 6020domain.com.au - January 18 at 9:02 AMSorrento Therapeutics, Inc. (0L85.L)finance.yahoo.com - January 9 at 10:46 AMSorrento WA 6020domain.com.au - December 29 at 3:42 PMSorrento Therapeutics Inc SRNEQmorningstar.com - November 5 at 10:27 AM29 Normanby Road Sorrento VIC 3943domain.com.au - October 15 at 5:35 PMSorrento, Italy - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - October 14 at 3:34 PM151 Seacrest Drive Sorrento WA 6020domain.com.au - October 10 at 9:09 PMSorrento holiday apartment accommodation with beach/lake nearby, internet access, balcony/terrace and air conholidaylettings.co.uk - October 9 at 7:15 PM9 Sunset Strip Sorrento VIC 3943domain.com.au - September 14 at 9:37 AMCourt rules Virpax CEO Anthony Mack breached his agreement with Sorrento Therapeuticsbizjournals.com - September 7 at 5:29 PM122 Campbell Street Sorrento QLD 4217domain.com.au - August 21 at 3:59 PMSorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bidfinance.yahoo.com - August 8 at 11:08 AMCheap Flights from Glasgow to Sorrentoskyscanner.net - August 3 at 1:31 PMCheap Flights from Edinburgh to Sorrentoskyscanner.net - July 29 at 11:29 PMCheap Flights from Bucharest to Sorrentoskyscanner.net - July 29 at 1:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAtara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.Compass TherapeuticsNASDAQ:CMPXCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Caribou BiosciencesNASDAQ:CRBUCaribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Sorrento TherapeuticsNASDAQ:SRNESorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.